NCCN Guidelines for Patients® | Lung Cancer - Non-Small Cell Lung Cancer

87 NCCN Guidelines for Patients ® : Lung Cancer – Non-Small Cell, 2018 BRAF V600E mutation Guide 24 lists treatment options for BRAF V600E mutation. Dabrafenib with trametinib is one option. If these treatments make you too sick, you may receive dabrafenib or vemurafenib alone. Another option is platinum-based chemotherapy. However, more research is needed to learn how well these treatments work. PD-L1 positive Guide 25 lists treatment options for cancers PD-L1 positive ≥50%. Pembrolizumab is an option for first- line treatment. Platinum-based chemotherapy may be an option if you can’t take pembrolizumab. The cancer may worsen while taking pembrolizumab. In this case, platinum-based chemotherapy may be an option. Read Guide 26 to learn more options for Adenocarcinoma, large cell, and unknown types . Read Guide 27 to learn more options for Squamous cell carcinoma . 7 Metastatic cancer BRAF V600E mutation | PD-L1 positive Guide 24. Treatment for BRAF V600E mutation What are the options? • Dabrafenib + trametinib • Start treatment for histologic type ◦◦ Adenocarcinomas, large cell, unknown types (see Guide 26 ) ◦◦ Squamous cell carcinoma (see Guide 27 ) Guide 25. Treatment for PD-L1 positive ≥50% What are the options? • Pembrolizumab • Start treatment for histologic type if you can’t take pembrolizumab ◦◦ Adenocarcinomas, large cell, unknown types (see Guide 26 ) ◦◦ Squamous cell carcinoma (see Guide 27 )

RkJQdWJsaXNoZXIy MTE3MTE1